GlassScriptPhysician profile
Enrique Jacome
NPI 1942300942
$3,760.47
in general payments reported to CMS, 2019-2025
32 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $345 · 2021: $819 · 2022: $807 · 2023: $570 · 2024: $614 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,508.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,555.98 | 2019-2025 | |
| Myovant Sciences INC. | $284.29 | 2021-2022 | |
| Biogen, INC. | $235.84 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $233.63 | 2024-2025 | |
| Aspira Women'S Health INC | $225.81 | 2020-2024 | Ova1 |
| Hologic Sales and Service, LLC | $168.68 | 2019-2023 | Thinprep 2000 Processor |
| Astellas Pharma US INC | $146.87 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $120.77 | 2019-2023 | Injectafer |
| Pfizer INC. | $117.40 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $97.69 | 2023-2025 | |
| Lupin INC. | $63.46 | 2020 | |
| Sumitomo Pharma America, INC. | $55.70 | 2023-2025 | Myfembree, Gemtesa |
| Amag Pharmaceuticals, INC. | $41.31 | 2019-2020 | |
| Abbott Laboratories | $38.22 | 2020-2021 | |
| Evofem Biosciences, INC. | $36.26 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $35.73 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $33.35 | 2019-2022 | |
| Coloplast Corp | $29.62 | 2019-2020 | |
| Axonics, INC. | $27.43 | 2022 | |
| Galderma Laboratories, L.P. | $25.46 | 2024 | Dysport |
| Bayer Healthcare Pharmaceuticals INC. | $25.18 | 2022 | |
| Allergan, INC. | $23.37 | 2020 | |
| Davol INC. | $20.61 | 2024 | Arista Ah Flexitip |
| Merck Sharp & Dohme LLC | $16.86 | 2019 | |
| Ethicon US, LLC | $16.43 | 2019 | |
| Boston Scientific Corporation | $15.30 | 2024 | Solyx Sis System |
| Therapeuticsmd, INC. | $14.02 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.18 | 2019 | |
| Avion Pharmaceuticals | $12.32 | 2022 | |
| Minerva Surgical, INC | $11.81 | 2021 | |
| Organon LLC | $11.50 | 2022 | |
| Channel Medsystems, INC. | $6.39 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enrique Jacome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.